表紙
市場調査レポート

PharmaPoint:アトピー性皮膚炎 - 世界における医薬品の予測と市場分析

PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024

発行 GlobalData 商品コード 296462
出版日 ページ情報 英文 228 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
PharmaPoint:アトピー性皮膚炎 - 世界における医薬品の予測と市場分析 PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024
出版日: 2015年11月03日 ページ情報: 英文 228 Pages
概要

アトピー性皮膚炎の治療薬市場は、この10年間は比較的変化が少なく、飽和状態でした。しかし、来るべき10年間は、生物製剤による最初の製品が登場し、先例を作って、後進に道を開くことになります。

当レポートでは、世界におけるアトピー性皮膚炎の治療薬市場について調査分析し、疾患の概要、収益実績と予測、主要トピック(戦略的競合企業の評価、市場の特性、アンメットニーズ、臨床試験マッピングなど)、パイプライン分析、現在/将来の市場競合分析(促進要因・抑制要因、課題など)を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 症状

第4章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
    • 10歳以下の子供は、発症の可能性が3倍高くなる傾向に
    • 家族歴のある場合は、発症リスクが6倍に
    • アレルゲンがあると、発症リスクが6倍に
    • 4ヶ月以上の母乳育児が、アトピー性皮膚炎から子供を保護
    • 併発しやすいのは、喘息、アレルギー性鼻炎、アレルギー性結膜炎
    • 患者は、精神疾患を発症する可能性が3倍高い
  • 世界の動向
    • 米国
    • EU5ヶ国
    • 日本
    • 中国
    • インド
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
  • 予測の前提条件と手法
  • 疫学予測
    • 生涯の有病者数
    • 生涯の有病者数:年齢別
    • 生涯の有病者数:性別
    • 生涯の有病率:年齢標準化
    • 有病者数:重症度別
  • 議論
    • 疫学動向に関する結論
    • 分析の限界
    • 分析の強み

第5章 疾患の管理

  • 診断
  • 治療の概要
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • 中国
  • インド

第6章 競合評価

  • 概要
  • 戦略的競合企業の評価
  • 製品プロファイル - 主要ブランド
    • Protopic
    • Elidel
    • Cyclosporine
    • その他
  • 製品プロファイル - 認可外
    • Xolair
    • Actimmune

第7章 機会とアンメットニーズ

  • 概要
  • アンメットニーズ
  • アンメットニーズのギャップ分析
  • 機会

第8章 パイプライン評価

  • 概要
  • 臨床試験マッピング
  • 臨床試験:フェーズ・段階別
  • 臨床開発中の有望な薬剤

第9章 現在/将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Astellas
    • Meda
    • Regeneron
    • Anacor

第10章 市場の見通し

  • 世界市場
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • 中国
  • インド

第11章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC120PIDR

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

By the mid-to-late term of GlobalData's 2014 to 2024 forecast, Sanofi/Regeneron's dupilumab is expected to reshape the adult moderate and severe treatment landscape and to slowly enter the market for younger patients with milder forms of the disease.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US.

Exciting times lay ahead for the atopic dermatitis marketplace, as the above events are due to occur against the backdrop of increasing research into the multiple etiologies that give rise to the disease. With existing unmet need for a better treatment armamentarium for severe, recalcitrant patients and an estimated drug-treated population that hovers around the 110 million mark over the next decade, atopic dermatitis represents an attractive dermatology sector for drug developers, and this should fuel commercial interest into this marketplace.

Highlights

Key Questions Answered

  • How will the atopic dermatitis market (sales and patient numbers) evolve over the 10-year forecast period from 2014 to 2024?
  • Which brands and specific drug classes did physicians select for their atopic dermatitis patients in 2014 and how do they foresee their prescribing behavior evolving over the next five years?
  • How will the launch of late-stage pipeline therapies such as dupilumab and AN2728 shape the future treatment landscape?
  • What are the remaining unmet needs and opportunities for drug developers within the atopic dermatitis market?

Key Benefits

  • The main drivers of growth in the atopic dermatitis over the 2014-2024 forecast period include the launch of the first biologic; Sanofi/Regeneron's dupilumab, and continued uptake of calcineurin inhibitors of systemic therapies.
  • Owing to high genericization, no distinct trends in corporate strategy exist within the atopic dermatitis market. However, over the coming decade, the introduction of biologics, in particular interleukin (IL) inhibitors, will emerge as a key future strategy for this marketplace.
  • High unmet need exists for a better treatment armamentarium for severe, recalcitrant patients. This patient segment remains underserved as physicians have few to no pharmacological options following treatment failure with or intolerability to cyclosporine, and as a result physicians often resort to prescribing off-label therapies.
  • Although dupilumab is forecast to gain a foothold in the severe population by late-forecast, it will not completely eradicate the high unmet need within the refractory group in the severe patient segment. There will still be a gap for other novel systemics, as dermatologists stress a desire for more than one treatment option to be added to their armamentarium.

Scope

  • Overview of atopic dermatitis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
  • Annualized atopic dermatitis therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2014 to 2024.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the atopic dermatitis therapeutics markets.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-to-late stage pipeline drugs.
  • Analysis of the current and future market competition in the global atopic dermatitis therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global atopic dermatitis therapeutics markets.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global atopic dermatitis therapeutics markets in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global atopic dermatitis therapeutics markets from 2014-2024.
  • Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. France
    • 4.3.3. Germany
    • 4.3.4. Italy
    • 4.3.5. Spain
    • 4.3.6. UK
    • 4.3.7. Japan
    • 4.3.8. China
    • 4.3.9. India
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast for Atopic Dermatitis (2014-2024)
    • 4.5.1. One-Year Total Prevalent Cases of Atopic Dermatitis
    • 4.5.2. Age-Specific One-Year Total Prevalent Cases of Atopic Dermatitis
    • 4.5.3. Sex-Specific One-Year Total Prevalent Cases of Atopic Dermatitis
    • 4.5.4. Age-Standardized One-Year Total Prevalence of Atopic Dermatitis
    • 4.5.5. One-Year Total Prevalent Cases of Atopic Dermatitis by Severity
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines
    • 5.1.3. Leading Prescribed Drugs for the Treatment of RA
    • 5.1.4. Clinical Practice
  • 5.2. US
  • 5.3. 5EU
  • 5.4. Japan

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Strategic Competitor Assessment
  • 6.3. Product Profiles - Major Brands
    • 6.3.1. Protopic (tacrolimus)
    • 6.3.2. Elidel
    • 6.3.3. Cyclosporine (numerous generic names)
    • 6.3.4. Other Therapeutic Drug Classes Used in Atopic Dermatitis
  • 6.4. Product Profiles - Off-Label Therapies
    • 6.4.1. Xolair (omalizumab)
    • 6.4.2. Actimmune (interferon gamma-1b)

7. Opportunity and Unmet Need

  • 7.1. Overview
    • 7.1.1. A Systemic Drug for Severe Recalcitrant Patients
    • 7.1.2. Tests that Stratify Patients and Allow for a Tailored Treatment Approach
    • 7.1.3. A Drug that Effectively Controls Patients' Pruritus
    • 7.1.4. Further Research into the Pathophysiology of Atopic Dermatitis
    • 7.1.5. A Drug that Induces Disease Remission
    • 7.1.6. Improved Quality of Life for Both Patients and their Carers

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Therapy Type
  • 8.3. Promising Drugs in Clinical Development
    • 8.3.1. Dupilumab (SAR231893/ REGN668)
    • 8.3.2. AN2728
    • 8.3.3. Other Drugs in Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Astellas
    • 9.3.2. Meda
    • 9.3.3. Sanofi/Regeneron/Boehringer Ingelheim
    • 9.3.4. Anacor

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Global Drivers and Barriers
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Atopic Dermatitis Patients
    • 11.4.2. Percent Drug-treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in this Study
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Author
    • 11.7.2. Reviewer
    • 11.7.3. Epidemiologist
    • 11.7.4. Global Director of Therapy Analysis and Epidemiology
    • 11.7.5. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Symptoms of Atopic Dermatitis
  • Table 2: Risk Factors and Comorbidities of Atopic Dermatitis
  • Table 3: Diagnostic Criteria for Atopic Dermatitis
  • Table 4: The Hanifin and Rajka Diagnostic Criteria for Atopic Dermatitis
  • Table 5: 9MM, Sources of Epidemiological Data used for the Forecast for the One-Year Total Prevalent Cases of Atopic Dermatitis
  • Table 6: 9MM, Sources of Epidemiological Data Used for the Segmentation of One-Year Total Prevalent Cases of Atopic Dermatitis by Severity
  • Table 7: 9MM, One-Year Total Prevalent Cases of Atopic Dermatitis, All Ages, Both Sexes, N, 2014-2024
  • Table 8: 9MM, One-Year Total Prevalent Cases of Atopic Dermatitis, by Age Group, Both Sexes, N, (Row %), 2014
  • Table 9: 9MM, One-Year Total Prevalent Cases of Atopic Dermatitis, by Sex, All Ages, N (Row %), 2014
  • Table 10: 9MM, One-Year Total Prevalent Cases of Atopic Dermatitis by Severity, All Ages, Both Sexes, N (Row %), 2014
  • Table 11: Treatment Guidelines for Atopic Dermatitis
  • Table 12: Most Prescribed Drugs for Atopic Dermatitis by Severity in the Global Markets, 2014
  • Table 13: Country Profile - US
  • Table 14: Country Profile - 5EU
  • Table 15: Country Profile - Japan
  • Table 16: Leading Treatments for Atopic Dermatitis, 2014
  • Table 17: Product Profile - Protopic
  • Table 18: Clinical Response Data of Protopic (0.03% and 0.1%) versus Vehicle Ointment at Week 12 from One Study in Pediatric Patients and Two Combined Studies in Adult Patients
  • Table 19: Protopic SWOT Analysis, 2015
  • Table 20: Global Sales Forecasts ($m) for Protopic, 2014-2024
  • Table 21: Product Profile - Elidel
  • Table 22: Combined Clinical Efficacy Results of Elidel versus Vehicle Cream at Week 6 from Two Phase III Studies
  • Table 23: Elidel SWOT Analysis, 2015
  • Table 24: Global Sales Forecasts ($m) for Elidel, 2014-2024
  • Table 25: Product Profile - Cyclosporine
  • Table 26: Cyclosporine SWOT Analysis, 2015
  • Table 27: Global Sales Forecasts ($m) for Cyclosporine, 2014-2024
  • Table 28: Summary of Other Therapeutic Classes for Atopic Dermatitis, 2015
  • Table 29: Product Profile - Xolair
  • Table 30: Xolair SWOT Analysis, 2015
  • Table 31: Global Sales Forecasts ($m) Xolair, 2014-2024
  • Table 32: Product Profile - Actimmune
  • Table 33: Actimmune SWOT Analysis, 2015
  • Table 34: Global Sales Forecasts ($m) Actimmune, 2014-2024
  • Table 35: Overall Unmet Needs in Atopic Dermatitis - Current Level of Attainment
  • Table 36: Clinical Unmet Needs in Atopic Dermatitis - Gap Analysis, 2015
  • Table 37: Late-Stage Atopic Dermatitis Pipeline, 2015
  • Table 38: Product Profile - Dupilumab
  • Table 39: Ongoing Clinical Trials of Dupilumab in Atopic Dermatitis Patients, as of December 2014
  • Table 40: Dupilumab SWOT Analysis, 2015
  • Table 41: Global Sales Forecasts ($m) for Dupilumab, 2014-2024
  • Table 42: Product Profile - AN2728
  • Table 43: Efficacy Results for AN2728 in Mild to Moderate Adolescent Atopic Dermatitis Patients (Day 29)
  • Table 44: AN2728 SWOT Analysis, 2015
  • Table 45: Global Sales Forecasts ($m) for AN2728, 2014-2024
  • Table 46: Drugs in Early-stage Clinical Development for Atopic Dermatitis, 2015
  • Table 47: Key Companies in the Atopic Dermatitis Market, 2015
  • Table 48: Astellas Pharma's Atopic Dermatitis Portfolio Assessment, 2015
  • Table 49: Astellas Pharma SWOT Analysis, 2015
  • Table 50: Meda's Atopic Dermatitis Portfolio Assessment, 2015
  • Table 51: Meda SWOT Analysis, 2015
  • Table 52: Regeneron's Atopic Dermatitis Portfolio Assessment, 2015
  • Table 53: Regeneron SWOT Analysis, 2015
  • Table 54: Anacor's Atopic Dermatitis Portfolio Assessment, 2015
  • Table 55: Anacor's SWOT Analysis, 2015
  • Table 56: Global Sales Forecasts ($m) for Atopic Dermatitis, 2014-2024
  • Table 57: Global Atopic Dermatitis Market - Drivers and Barriers, 2014-2024
  • Table 58: Sales Forecasts ($m) for Atopic Dermatitis in the US, 2014-2024
  • Table 59: Key Events Impacting Sales for Atopic Dermatitis in the US, 2014-2024
  • Table 60: Drivers and barriers of the atopic dermatitis market in the US during the forecast period.
  • Table 61: Sales Forecasts ($m) for Atopic Dermatitis in the 5EU, 2014-2024
  • Table 62: Key Event Impacting Sales for Atopic Dermatitis in 5EU, 2014-2024
  • Table 63: Atopic Dermatitis Market in 5EU - Drivers and Barriers, 2014-2024
  • Table 64: Sales Forecasts ($m) for Atopic Dermatitis in Japan, 2012-2022
  • Table 65: Key Event Impacting Sales for Atopic Dermatitis in Japan, 2014-2024
  • Table 66: Atopic Dermatitis Market in Japan - Drivers and Barriers, 2014-2024
  • Table 67: Key Launch Dates
  • Table 68: Key Patent Expiries
  • Table 69: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Immunologic Pathway Involved in Healthy, Acute Atopic Dermatitis, and Chronic Atopic Dermatitis Skin
  • Figure 2: 9MM, One-Year Total Prevalent Cases of Atopic Dermatitis, All Ages, Both Sexes, N, 2014-2024
  • Figure 3: 9MM, One-Year Total Prevalent Cases of Atopic Dermatitis, by Age Group, Both Sexes, N, 2014
  • Figure 4: 9MM, One-Year Total Prevalent Cases of Atopic Dermatitis, by Sex, All Ages, N, 2014
  • Figure 5: 9MM, Age-Standardized One-Year Total Prevalence (%) of Atopic Dermatitis, All Ages, Both Sexes, 2014
  • Figure 6: 9MM, One-Year Total Prevalent Cases of Atopic Dermatitis by Severity, All Ages, Both Sexes, N, 2014
  • Figure 7: Flow Chart of the Diagnosis and Management of Atopic Dermatitis
  • Figure 8: Atopic Dermatitis Therapeutics - Clinical Trials by Therapy Type and Development Stage, October 2015
  • Figure 9: Atopic Dermatitis - Phase III Pipeline, December 2014
  • Figure 10: Competitive Assessment of Late-Stage Pipeline Agents in Atopic Dermatitis, 2014-2024
  • Figure 11: Company Portfolio Gap Analysis in Atopic Dermatitis, 2014-2024
  • Figure 12: Global Sales for Atopic Dermatitis by Region, 2012-2022
  • Figure 13: Sales for Atopic Dermatitis in the US by Drug Class, 2014-2024
  • Figure 14: Sales for Atopic Dermatitis in 5EU by Drug Class, 2014-2024
  • Figure 15: Sales for Atopic Dermatitis in Japan by Drug Class, 2014-2024
Back to Top